Eli Lilly: Additional $4.5bn to support its industrial scale-up
Eli Lilly is set to invest an additional $4.5bn across two of its Lebanon, Indiana sites, bringing its total expansion commitments in the state to over $21bn since 2020. The group has highlighted its evolving pipeline and the projected demand for its treatments.
Eli Lilly has said that the investment will target Lilly Lebanon API, a future active pharmaceutical ingredient production site, and Lilly Lebanon Advanced Therapies, whose opening was announced on May 6. The latter is presented as the group's first facility dedicated to genetic medicine, with production spanning from clinical trials to commercial supply.
The scope of the announcement goes beyond a simple capacity increase. Lilly is strengthening its industrial infrastructure around its primary growth drivers, including Zepbound and Mounjaro. The group is also preparing for the ramp-up of Foundayo, its FDA-approved daily weight-loss pill, and retatrutide, which remains in late-stage development for obesity and cardiometabolic diseases.
This expansion comes as Mounjaro has overtaken Merck's Keytruda to become the world's best-selling drug, according to S&P Capital IQ. The investment thus aims to support Lilly's current engines while preparing the next wave of treatments. The Lebanon API site is scheduled to open in 2027, with the ambition of becoming the largest active ingredient production site in the US.
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (14.4%);
- immunology diseases (8.1%);
- neurology (2.1%): primarily drugs used in treating depression and schizophrenia;
- other (1.4%).
Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
